Demyelination and other neurological adverse events after anti-TNF therapy

Autoimmunity Reviews

Volumn 13, Issue 1, 2014, Pages 54-58

  Kaltsonoudis, Evripidis ^a   Voulgari, Paraskevi V ^a   Konitsiotis, Spyridon ^a   Drosos, Alexandros A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Multiple sclerosis; Neurological adverse events; SpA; STNF; STNF ; TACE; TmTNF; TmTNF ; TNF ; TNF antagonists; TNFR1,2; TNFR2

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; LENERCEPT; MYELIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY;

ALLERGIC ENCEPHALOMYELITIS; APOPTOSIS; AXONAL SENSORIMOTOR POLYNEUROPATHY; BLOOD BRAIN BARRIER; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DEMYELINATING DISEASE; DEMYELINATION; DRUG WITHDRAWAL; GUILLAIN BARRE SYNDROME; HUMAN; LONG TERM EXPOSURE; MONONEUROPATHY MULTIPLEX; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MYELITIS; NEUROLOGICAL COMPLICATION; NONHUMAN; OLIGODENDROGLIA; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; REMYELINIZATION; REVIEW; TH1 CELL; TH17 CELL; THERAPY;

BBB; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CNS; DISEASE MODIFYING ANTI-RHEUMATIC DRUGS; DMARDS; EAE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IL; INF-Γ; INTERFERON Γ; INTERLEUKIN; MONOMERIC TYPE-2 TRANSMEMBRANE PRECURSOR PROTEIN; MS; MULTIPLE SCLEROSIS; NEUROLOGICAL ADVERSE EVENTS; NOD; NONOBESE DIABETIC; RA; RHEUMATOID ARTHRITIS; SOLUBLE FORM OF CYTOKINE; SPA; SPONDYLOARTHROPATHIES; STNF; STNFΑ; TACE; TMTNF; TMTNFΑ; TNF RECEPTOR; TNFΑ; TNFΑ ANTAGONISTS; TNFΑ CONVERTING ENZYME; TNFR1,2; TNFR2; TUMOR NECROSIS FACTOR Α;

ANIMALS; ANTIBODIES; AUTOIMMUNE DISEASES; DEMYELINATING DISEASES; HUMANS; MULTIPLE SCLEROSIS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886952980     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.09.002     Document Type: Review

References (53)

1. Atzeni F., Puttini P.S., Mutti A., Bugatti S., Cavagna L., Caporali R. Long-term safety of abatacept in patients with rheumatoid arthritis. Autoimmun Rev 2013, 12:1115-1117.
2. Atzeni F., Sarzi-Puttini P., Botsios C., Carletto A., Cipriani P., Favalli E.G., et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 2012, 12:225-229.
3. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279.
4. Ben-Horin S., Kopylov U., Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2013, 13:24-30.
5. Sfikakis P.P., Tsokos G.C. Towards the next generation of anti-TNF drugs. Clin Immunol 2011, 141:231-235.
6. Lin J., Ziring D., Desai S., Kim S., Wong M., Korin Y., et al. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008, 126:13-30.
7. Efe C. Drug induced autoimmune hepatitis and TNF-α blocking agents: is there a real relationship?. Autoimmun Rev 2013, 12:337-339.
8. Fiorino G., Danese S., Pariente B., Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha;agents. Autoimmun Rev 2013, 13:15-19.
9. Borchers A.T., Leibushor N., Cheema G.S., Naguwa S.M., Gershwin M.E. Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. J Autoimmun 2011, 37:273-288.
10. van Oosten B.W., Barkhof F., Truyen L., Boringa J.B., Bertelsmann F.W., von Blomberg B.M., et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996, 47:1531-1534.
11. Sicotte N.L., Voskuhl R.R. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001, 57:1885-1888.
12. Mohan N., Edwards E.T., Cupps T.R., Oliverio P.J., Sandberg G., Crayton H., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001, 44:2862-2869.
13. Robinson W.H., Genovese M.C., Moreland L.W. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?. Arthritis Rheum 2001, 44:1977-1983.
14. Cisternas M., Gutiérrez M., Jacobelli S. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al. Arthritis Rheum 2002, 46:3107-3108.
15. Titelbaum D.S., Degenhardt A., Kinkel R.P. Anti-tumor necrosis factor alpha-associated multiple sclerosis. AJNR Am J Neuroradiol 2005, 26:1548-1550.
16. Ruiz-Jimeno T., Carvajal A., Mata C., Aurrecoechea E. Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab. J Rheumatol 2006, 33:1457-1458.
17. Dubcenco E., Ottaway C.A., Chen D.L., Baker J.P. Neurological symptoms suggestive of demyelination in Crohn's disease after infliximab therapy. Eur J Gastroenterol Hepatol 2006, 18:565-566.
18. Toussirot E., Pertuiset E., Martin A., Melac-Ducamp S., Alcalay M., Grardel B., et al. Club Rheumatismes et Inflammation. Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance. J Rheumatol 2006, 33:1027-1028.
19. Magnano M.D., Robinson W.H., Genovese M.C. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol 2004, 22(5 Suppl. 35):S134-S140.
20. Mejico L.J. Infliximab-associated retrobulbar optic neuritis. Arch Ophthalmol 2004, 122:793-794.
21. Shin I.S., Baer A.N., Kwon H.J., Papadopoulos E.J., Siegel J.N. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 2006, 54:1429-1434.
22. Gomez-Gallego M., Meca-Lallana J., Fernandez-Barreiro A. Multiple sclerosis onset during etanercept treatment. Eur Neurol 2008, 59:91-93.
23. Winkelmann A., Patejdl R., Wagner S., Benecke R., Zettl U.K. Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy. J Neurol 2008, 255(Suppl. 6):109-114.
24. Mignarri A., Dotti M.T., Battisti C., Vallone I., Federico A. Occurrence of ankylosing spondylitis and multiple sclerosis-like syndrome in a HLA-B27 positive patient. Neurol Sci 2009, 30:329-332.
25. Pfueller C.F., Seipelt E., Zipp F., Paul F. Multiple sclerosis following etanercept treatment for ankylosing spondylitis. Scand J Rheumatol 2008, 37:397-399.
26. Lozeron P., Denier C., Lacroix C., Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009, 66:490-497.
27. Fromont A., De Seze J., Fleury M.C., Maillefert J.F., Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 2009, 45:55-57.
28. Bernatsky S., Renoux C., Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis 2010, 69:1691-1693.
29. Ramos-Casals M., Perez-Alvarez Roberto, Diaz-Lagares C., Cuadrado M.J., Khamashta M.A. BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev 2010, 9:188-193.
30. Solomon A.J., Spain R.I., Kruer M.C., Bourdette D. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler 2011, 17:1472-1487.
31. Caminero A., Comabella M., Montalban X. Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story. J Neuroimmunol 2011, 234:1-6.
32. Nozaki K., Silver R.M., Stickler D.E., Abou-Fayssal N.G., Giglio P., Kamen D.L., et al. Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci 2011, 342:352-355.
33. Molloy E.S., Calabrese L.H. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 2012, 64:3043-3051.
34. Fernández-Espartero M.C., Pérez-Zafrilla B., Naranjo A., Esteban C., Ortiz A.M., Gómez-Reino J.J., et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 2011, 40:330-337.
35. Bosch X., Saiz A., Ramos-Casals M., BIOGEAS Study Group Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol 2011, 7(3):165-172.
36. Faillace C., de Almeida J.R., de Carvalho J.F. Optic neuritis after infliximab therapy. Rheumatol Int 2013, 33:1101-1103.
37. Andreadou E., Kemanetzoglou E., Brokalaki Ch., Evangelopoulos M.E., Kilidireas C., Rombos A., et al. Demyelinating disease following anti-TNFα treatment: a causal or coincidental association? Report of four cases and review of the literature. Case Rep Neurol Med 2013, 2013:671935.
38. Van Hauwermeiren F., Vandenbroucke R.E., Libert C. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev 2011, 22:311-319.
39. Kollias G., Douni E., Kassiotis G., Kontoyiannis D. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 1999, 169:175-194.
40. Kassiotis G., Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 2001, 193:427-434.
41. Lim S.Y., Constantinescu C.S. TNF-α: a paradigm of paradox and complexity in multiple sclerosis and its animal models. Open Autoimmun J 2010, 2:160-170.
42. Sharief M.K., Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991, 325:467-472.
43. Sharief M.K., Hentges R., Ciardi M. Intrathecal immune response in patients with the post-polio syndrome. N Engl J Med 1991, 325:749-755.
44. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N Engl J Med 2000, 343:938-952.
45. van Boxel-Dezaire A.H., Hoff S.C., van Oosten B.W., Verweij C.L., Dräger A.M., Adèr H.J., et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 1999, 45:695-703.
46. Panitch H.S., Hirsch R.L., Haley A.S., Johnson K.P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987, 1(8538):893-895.
47. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999, 53:457-465. No authors listed.
48. Pardridge W.M. CNS drug design based on principles of blood-brain barrier transport. J Neurochem 1998, 70:1781-1792.
49. Cope A., Ettinger R., McDevitt H. The role of TNF alpha and related cytokines in the development and function of the autoreactive T-cell repertoire. Res Immunol 1997, 148:307-312.
50. Mikuls T.R., Weaver A.L. Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Curr Rheumatol Rep 2003, 5:270-277.
51. Voulgari P.V., Alamanos Y., Nikas S.N., Bougias D.V., Temekonidis T.I., Drosos A.A. Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med 2005, 118:515-520.
52. Temekonidis T.I., Georgiadis A.N., Alamanos Y., Bougias D.V., Voulgari P.V., Drosos A.A. Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann Rheum Dis 2002, 61:822-825.
53. Midgard R., Grønning M., Riise T., Kvåle G., Nyland H. Multiple sclerosis and chronic inflammatory diseases. A case-control study. Acta Neurol Scand 1996, 93:322-328.